PDCD1 and cancer: In addressing the challenges of VISTA-targeted cancer immunotherapy, we introduce SNS-101, a pH-selective antibody designed to mitigate rapid clearance and cytokine release syndrome, enhancing the therapeutic efficacy of PD-1 inhibitors.